P. Nash
C. T. Ritchlin
P. Rahman
M. Shawi
E. Rampakakis
Y. Lee
A. Kollmeier
X. L. Xu
J. Sherlock
D. Cua
S. Khattri
E. Soriano
D. Mcgonagle
Griffiths University and University of Queensland, Rheumatology Research Unit, Maroochydore, Australia
University of Rochester, Allergy/Immunology and Rheumatology, Rochester, United States of America
Memorial University of Newfoundland, Craig L Dobbin Genetics Research Centre, Discipline of Medicine, Division of Rheumatology, St. John’s, Canada
Janssen Pharmaceutical Companies of Johnson & Johnson, Immunology Global Medical Affairs, Horsham, PA, United States of America
McGill University, Department of Psychiatry, Montreal, Canada
JSS Medical Research, Inc, Scientific Affairs, Montreal, Canada
Janssen Asia Pacific, Immunology Medical Affairs, Seoul, Korea, Rep. of (South Korea)
Janssen Research & Development, LLC, Immunology, San Diego, CA, United States of America
Janssen Research & Development, Raritan, United States of America
University of Oxford, Oxford, United Kingdom
Icahn School of Medicine at Mount Sinai Hospital - New York - United States of America
Hospital Italiano de Buenos Aires, Servicio de Reumatología, Buenos Aires, Argentina
University of Leeds and LTHT NIHR Biomedical Research Centre, Leeds, United Kingdom
Australia
United States
Canada
Republic of South Korea
United Kingdom
Argentina
N/A
Musculoskeletal
Dermatology
Psoriatic arthritis
C reactive protein
guselkumab (IV)
N/A
Randomized
Placebo Control
N/A
N/A
Janssen Pharmaceutical
N/A